Halozyme Therapeutics: The Story Brightens (NASDAQ:HALO)

Date:


Abstract creative financial graph with upward arrow and hands typing on laptop on background, forex and investment concept. Multiexposure

Igor Kutyaev/iStock via Getty Images

Today, we are following up on mid-cap biopharma concern Halozyme Therapeutics, Inc. (NASDAQ:HALO) as the company issued an important FY2024 guidance update on Thursday. The company also provided updated 5-Year guidance that



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related